Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen inKRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study
Titel:
Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen inKRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study
Auteur:
Schultheis, B. Reuter, D. Ebert, M.P. Siveke, J. Kerkhoff, A. Berdel, W.E. Hofheinz, R. Behringer, D.M. Schmidt, W.E. Goker, E. De Dosso, S. Kneba, M. Yalcin, S. Overkamp, F. Schlegel, F. Dommach, M. Rohrberg, R. Steinmetz, T. Bulitta, M. Strumberg, D.